Thermedical, Inc.
Thermedical is developing a proprietary thermal ablation therapy that can treat significantly larger tissue volumes using a single device than conventional technology. Thermedical is a privately held medical device company based in Waltham, Massachusetts. The Company is focused on the treatment and cure of Ventricular Tachycardia (VT), an irregular heartbeat that can lead to sudden cardiac arrest, and the treatment of soft tissue conditions. Both of these disease states require a tool that can predictably and efficiently ablate a much larger volume of tissue than conventional technology. Use of the Thermedical Ablation System for the treatment of VT is investigational. and is not approved for use or sale in any market.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
About us
Our Thermedical Ablation System employs Saline-Enhanced Radio Frequency (SERF) energy to overcome the challenges of traditional ablation tools and to treat large volumes of tissue in a more efficient manner. The Thermedical Ablation System and Needle is 510(k) cleared for the coagulation and ablation of soft tissue during percutaneous, laparoscopic and intraoperative surgical procedures.
The Company is currently developing a smaller catheter-based delivery system, Durablate™, that is designed specifically for the treatment of VT.
Thermedical® is a privately held medical device company based in Waltham, Massachusetts.
History
The Company was founded by Michael G. Curley, Ph.D., FHRS, and Patrick S. Hamilton, Ph.D. who met at the M.I.T. Hyperthermia Center as graduate students.
The Company was reorganized in Delaware as Thermedical in 2008. In 2012, the Thermedical® Ablation System and the Ablation Needle received initial U.S. Food & Drug Administration (FDA) clearance for the coagulation and ablation of soft tissue during percutaneous, laparoscopic, and intraoperative surgical procedures. This clearance was based on substantial preclinical testing carried out under multiple Small Business Innovation Research (SBIR) Grants from the National Institutes of Health (NIH) and on a matching grant from the Massachusetts Life Sciences Center.